03/11/2026
A 10-month-old Oklahoma baby is thriving with his vision intact thanks to a treatment that, until now, wasn’t available in our state.
Oklahoma Children’s OU Health has successfully performed the state’s first intra-arterial chemotherapy procedure for retinoblastoma, a rare eye cancer that primarily affects infants and young children.
This sight-saving treatment delivers targeted chemotherapy directly to the tumor, reducing side effects while preserving a child’s vision. Previously, families often had to travel across the country for this care. Now, this advanced therapy is available close to home.
Led by Dr. Michael Feldman, Oklahoma Children’s pediatric and endovascular neurosurgeon and assistant professor in the Department of Neurosurgery at The University of Oklahoma College of Medicine, a highly specialized team of experts from pediatric neurosurgery, oncology, ophthalmology, anesthesia, radiology, and pharmacy provided precise, compassionate care. The patient’s tumor shrank quickly, is now inactive, and he has retained his vision and is thriving.
This accomplishment reflects the strength of our multidisciplinary pediatric teams and our commitment to ensuring children across Oklahoma have access to world-class treatment without leaving the state.
At Oklahoma Children’s, we are dedicated to delivering leading-edge cancer care, advancing research and supporting families every step of the way.
